Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

Arianna Huffington's Thrive Global partners with Zepbound-maker Eli Lilly to share content on healthy habits where patients ...

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

LCCI Hyderabad will focus on scaling up Lilly’s innovation and efficiency by unlocking new technological advancements ...

Thrive Global announced today it is working with Eli Lilly and Company to embed behavior change tools and resources onto LillyDirect and into traditional Lilly consumer channels in order to complement ...

The GCC, to be known as the Lilly Capability Centre India (LCCI), will be the company’s second centre in the country, ...

Forty submissions, weeks of polls and several thousand votes from Herald-Leader subscribers have finally brought us to this ...

Havas is forging deeper into the GLP-1 space with a series of YouTube videos about the drug class and its impact on the world ...